Cumberland Pharmaceuticals Announces Presentation of Caldolor Data at American Academy of Pain Management Meeting

Cumberland Pharmaceuticals Announces Presentation of Caldolor Data at American
Academy of Pain Management Meeting

NASHVILLE, Tenn., Oct. 5 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals
Inc. (Nasdaq: CPIX) announced today that data from two key clinical trials for
Caldolor®, an intravenous formulation of ibuprofen approved for treatment of
pain and fever in adults, will be presented at the American Academy of Pain
Management's (AAPM) 20th Annual Clinical Meeting to be held in Phoenix, Ariz.,
on October 8-11, 2009.

Data from the following clinical trials of Caldolor will be displayed in
poster presentations on Saturday, October 10, 2009, from 1:30-3:00 pm Mountain
Time:

-- A phase III dose ranging pain study entitled "A Multicenter,
Randomized,
Double-Blind, Placebo-Controlled Trial of Intravenous Ibuprofen for
the
Management of Postoperative Pain in Adults" will be presented by
principal author, Stephen R. Southworth, MD, FACS (study 008A, poster
#49).

-- A phase III abdominal hysterectomy pain study entitled "A Multicenter,
Randomized, Double-Blind, Placebo-Controlled Trial of Intravenous
Ibuprofen for the Management of Postoperative Pain in Adults,"
authored
by Peter Kroll, M.D., will be presented by co-author Laura Meadows,
BC,
CRCC (study 008B, poster #50).

In conjunction with the presentations, copies of the posters will be available
on Cumberland's website at http://investor.shareholder.com/cpix/events.cfm, or
by contacting the Company at 615-255-0068.

SOURCE: Cumberland Pharmaceuticals Inc.

About Caldolor

Caldolor is indicated for the management of mild to moderate pain and
management of moderate to severe pain as an adjunct to opioid analgesics, and
for the reduction of fever in adults. It is the first FDA approved intravenous
therapy for fever. Caldolor is contraindicated in patients with known
hypersensitivity to ibuprofen or other NSAIDs, patients with asthma,
urticaria, or allergic type reactions after taking aspirin or other NSAIDs.
Caldolor is contraindicated for use during the peri-operative period in the
setting of coronary artery bypass graft (CABG) surgery. Caldolor should be
used with caution in patients with prior history of ulcer disease or GI
bleeding, in patients with fluid retention or heart failure, in the elderly,
those with renal impairment, heart failure, liver impairment, and those taking
diuretics or ACE inhibitors. Blood pressure should be monitored during
treatment with Caldolor. For full prescribing information, visit
www.caldolor.com.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical
company focused on the acquisition, development and commercialization of
branded prescription products. The Company's primary target markets include
hospital acute care and gastroenterology. Cumberland markets Acetadote® for
the treatment of acetaminophen poisoning and Kristalose®, a prescription
laxative. The Company also recently received FDA approval for Caldolor®, the
first injectable treatment for pain and fever available in the United States,
and has now completed the commercial launch of that product. Cumberland is
dedicated to providing innovative products which improve quality of care for
patients. The Company recently completed the initial public offering of its
common stock.

For more information on Cumberland Pharmaceuticals, please visit
www.cumberlandpharma.com.

SOURCE Cumberland Pharmaceuticals Inc.

Investors, Angela Novak of Cumberland Pharmaceuticals, +1-615-255-0068,
investors@cumberlandpharma.com; or Media, Paula Lovell of Lovell
Communications Inc., +1-615-297-7766, lovell@lovell.com, for Cumberland
Pharmaceuticals